Login to Your Account

Other News To Note

Friday, April 15, 2011
Regulus Therapeutics Inc., of La Jolla, Calif., said it is collaborating with researchers at the University of California, San Diego (UCSD) School of Medicine seeking treatments for angiogenic diseases using microRNA therapeutics. The company said that the research will combine Regulus' microRNA platform with UCSD's expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies. Angiogenesis, which is the formation of new blood vessels, contributes to the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription